BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2834 http://bridgebio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma Inc

The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares - Dec 10th, 2019 12:56 pm
BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs - Dec 9th, 2019 12:30 pm
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Dec 6th, 2019 12:35 am
BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A - Dec 3rd, 2019 12:30 pm
PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome - Dec 2nd, 2019 1:00 pm
CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures - Nov 17th, 2019 12:28 am
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures - Nov 16th, 2019 10:30 pm
BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress - Nov 7th, 2019 9:13 pm
Hedge Funds Have Never Been This Bullish On BridgeBio Pharma, Inc. (BBIO) - Oct 24th, 2019 7:41 pm
BridgeBio Pharma Gene Therapy Subsidiaries Present Data Demonstrating Potential in Two Rare Disease Indications at the European Society of Gene and Cell Therapy Conference - Oct 22nd, 2019 11:30 am
QED and Parent Company BridgeBio Announce Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia - Oct 17th, 2019 11:00 am
Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options - Sep 24th, 2019 11:00 am
BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference - Sep 5th, 2019 8:00 pm
3 New Biotech Stocks That Keep On Soaring - Aug 30th, 2019 1:16 am
2 New Healthcare Stocks That Wall Street Thinks You Should Buy - Jul 27th, 2019 5:01 pm
Andreas Halvorsen Widens Position in Health Care Space With BridgeBio Pharma - Jul 2nd, 2019 5:48 pm
Recent IPOs show investor appetite is strong for biotechs - Jun 28th, 2019 7:14 pm